Close Menu

More articles about Molecular Diagnostics

Microbiology lab and industry stakeholders are increasingly working together to coordinate approaches and generate more clinical utility data for diagnostic testing.

The financing will go toward building out its sales teams in the US and Europe in order to market its multiplexed MDx tests for infectious diseases.

The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.

The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.

PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.

A survey by University of Nebraska researchers found that both specialists and primary care healthcare providers largely interpreted genetic testing results correctly.

Athena and its supporters have asked the Supreme Court to clarify patent eligibility, but Mayo recently countered that this is a job for legislators.

The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.

Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.

The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.

The T2Resistance Panel, which runs on the T2Dx instrument, detects 13 genes conferring antimicrobial resistance directly from whole blood in three to five hours.

While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.

The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.

Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.

The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.

The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.

AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.

The firm attributed the decline to reluctance of US customers to buy additional units of its Epi proColon colon cancer test amid reimbursement uncertainty.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.